Why RNA technology leads the immunity race against COVID-19

The quest to build immunity against the ravaging COVID-19 has been led by six vaccine developers.

The quest to build immunity against the ravaging COVID-19 has been led by six vaccine developers including Johnson & Johnson, AstraZeneca, Novavax, Pfizer/BioNTech, Gamaleya, Moderna and Sinovac. They all made it to the third phase of clinical trials in 2020 out 320 Covid-19 vaccine candidate

```

Members Only

Login or create an account to continue

This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.

New to BusinessDay? Register now and start reading.

```